Correlation Between Veracyte and Enanta Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Veracyte and Enanta Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Enanta Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Veracyte and Enanta Pharmaceuticals, you can compare the effects of market volatilities on Veracyte and Enanta Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Enanta Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Enanta Pharmaceuticals.

Diversification Opportunities for Veracyte and Enanta Pharmaceuticals

-0.79
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Veracyte and Enanta is -0.79. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Enanta Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enanta Pharmaceuticals and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Enanta Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enanta Pharmaceuticals has no effect on the direction of Veracyte i.e., Veracyte and Enanta Pharmaceuticals go up and down completely randomly.

Pair Corralation between Veracyte and Enanta Pharmaceuticals

Given the investment horizon of 90 days Veracyte is expected to generate 0.8 times more return on investment than Enanta Pharmaceuticals. However, Veracyte is 1.25 times less risky than Enanta Pharmaceuticals. It trades about 0.09 of its potential returns per unit of risk. Enanta Pharmaceuticals is currently generating about -0.15 per unit of risk. If you would invest  3,907  in Veracyte on October 20, 2024 and sell it today you would earn a total of  151.00  from holding Veracyte or generate 3.86% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Veracyte  vs.  Enanta Pharmaceuticals

 Performance 
       Timeline  
Veracyte 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.
Enanta Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enanta Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Veracyte and Enanta Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Veracyte and Enanta Pharmaceuticals

The main advantage of trading using opposite Veracyte and Enanta Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Enanta Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enanta Pharmaceuticals will offset losses from the drop in Enanta Pharmaceuticals' long position.
The idea behind Veracyte and Enanta Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years